Modern Approaches to Mouse Genome Editing Using the CRISPR-Cas Toolbox and Their Applications in Functional Genomics and Translational Research
- PMID: 37486514
- DOI: 10.1007/978-3-031-33325-5_2
Modern Approaches to Mouse Genome Editing Using the CRISPR-Cas Toolbox and Their Applications in Functional Genomics and Translational Research
Abstract
Mice have been used in biological research for over a century, and their immense contribution to scientific breakthroughs can be seen across all research disciplines, with some of the main beneficiaries being the fields of medicine and life sciences. Genetically engineered mouse models (GEMMs), along with other model organisms, are fundamentally important research tools frequently utilised to enhance our understanding of pathophysiology and biological mechanisms behind disease. In the 1980s, it became possible to precisely edit the mouse genome to create gene knockout and knock-in mice, although with low efficacy. Recent advances utilising CRISPR-Cas technologies have considerably improved our ability to do this with ease and precision, while also allowing the generation of desired genetic variants from single nucleotide substitutions to large insertions/deletions. It is now quick and relatively easy to genetically edit somatic cells which were previously more recalcitrant to traditional approaches. Further refinements have created a 'CRISPR toolkit' that has expanded the use of CRISPR-Cas beyond gene knock-ins and knockouts. In this chapter, we review some of the latest applications of CRISPR-Cas technologies in GEMMs, including nuclease-dead Cas9 systems for activation or repression of gene expression, base editing and prime editing. We also discuss improvements in Cas9 specificity, targeting efficacy and delivery methods in mice. Throughout, we provide examples wherein CRISPR-Cas technologies have been applied to target clinically relevant genes in preclinical GEMMs, both to generate humanised models and for experimental gene therapy research.
© 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Similar articles
-
Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research.Mil Med Res. 2023 Mar 10;10(1):12. doi: 10.1186/s40779-023-00447-x. Mil Med Res. 2023. PMID: 36895064 Free PMC article. Review.
-
New Developments in CRISPR/Cas-based Functional Genomics and their Implications for Research Using Zebrafish.Curr Gene Ther. 2017;17(4):286-300. doi: 10.2174/1566523217666171121164132. Curr Gene Ther. 2017. PMID: 29173171 Review.
-
Designing Genetically Engineered Mouse Models (GEMMs) Using CRISPR Mediated Genome Editing.Methods Mol Biol. 2022;2429:515-531. doi: 10.1007/978-1-0716-1979-7_36. Methods Mol Biol. 2022. PMID: 35507186
-
Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology.J Genet Genomics. 2016 May 20;43(5):251-62. doi: 10.1016/j.jgg.2016.03.001. Epub 2016 Mar 11. J Genet Genomics. 2016. PMID: 27165865 Review.
-
Boosting targeted genome editing using the hei-tag.Elife. 2022 Mar 25;11:e70558. doi: 10.7554/eLife.70558. Elife. 2022. PMID: 35333175 Free PMC article.
Cited by
-
The CRISPR-Cas9 System Is Used to Edit the Autoimmune Regulator Gene in Vitro and in Vivo.Adv Exp Med Biol. 2025;1471:269-283. doi: 10.1007/978-3-031-77921-3_10. Adv Exp Med Biol. 2025. PMID: 40067591
-
NanoTag is an improved method to map interactions between DNA and proteins not requiring IgG.Sci Rep. 2025 Aug 6;15(1):28672. doi: 10.1038/s41598-025-13316-5. Sci Rep. 2025. PMID: 40764348 Free PMC article.
-
Mouse models of chronic lymphocytic leukemia and Richter transformation: what we have learnt and what we are missing.Front Immunol. 2024 Jun 6;15:1376660. doi: 10.3389/fimmu.2024.1376660. eCollection 2024. Front Immunol. 2024. PMID: 38903501 Free PMC article. Review.
References
-
- Acosta S, Fiore L, Carota IA, Oliver G (2018) Use of two gRNAs for CRISPR/Cas9 improves bi-allelic homologous recombination efficiency in mouse embryonic stem cells. Genesis 56. https://doi.org/10.1002/DVG.23212
-
- Aida T, Wilde JJ, Yang L et al (2020) Prime editing primarily induces undesired outcomes in mice. bioRxiv:2020.08.06.239723. https://doi.org/10.1101/2020.08.06.239723
-
- Alonso A, Logroscino G, Jick SS, Hernán MA (2009) Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol 16:745–751. https://doi.org/10.1111/J.1468-1331.2009.02586.X - DOI - PubMed - PMC
-
- Amoasii L, Long C, Li H et al (2017) Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci Transl Med:9. https://doi.org/10.1126/SCITRANSLMED.AAN8081
-
- Bhagwan JR, Denning C, Collins E et al (2019) Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the AAVS1 locus as not an entirely safe harbour. F1000Res 8. https://doi.org/10.12688/F1000RESEARCH.19894.2
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources